Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

DataMeds AI (MEDS) Stock Price & Analysis

216 Followers

MEDS Stock Chart & Stats

$0.74-$0.13(-14.60%)
At close: 4:00 PM EST
$2$4$6Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.55 - $1.09
52-Week Range
$0.55 - $35.51
Previous Close
$0.87
Volume
N/A
Average Volume (3M)
1.87M
Market Cap
$3.91M
Enterprise Value
$38.31M
Total Cash (Recent Filing)
$476.60K
Total Debt (Recent Filing)
$19.84M
Price to Earnings (P/E)
―
Beta
0.17
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Exclusive GLP-1 Platform License

The exclusive REBOOT license adds specialized AI capabilities to DataMeds' direct-to-consumer weight-management offering. Its long-duration structure and revenue-sharing model could support product differentiation, recurring engagement, and broader commercialization if execution converts the technology into sustainable revenue.

Helomics Diagnostics Expansion

The Helomics acquisition broadens DataMeds beyond GLP-1 and healthcare software into laboratory and oncology services. A certified lab, existing CRO operations, and planned expansion of molecular profiling could create a more diversified healthcare platform and additional channels for future revenue.

Liability And Legal Cleanup

Eliminating approximately $19 million of disputed liabilities and resolving litigation removes a significant legacy overhang. The cleanup can simplify the capital structure, reduce legal uncertainty, and improve management's ability to focus resources on operating initiatives and strategic partnerships.

Bears Say

Severe Profitability Deterioration

The company currently lacks a sustainable profit engine: revenue has fallen sharply while gross, operating, and net margins are deeply negative. This cost-to-revenue mismatch limits internally funded growth and means strategic initiatives must overcome substantial operating losses before they can strengthen the business.

Persistent Cash Burn

Sustained operating and free-cash-flow losses indicate that the business consumes substantial cash rather than financing itself. Continued burn increases dependence on external capital, restricts investment flexibility, and leaves less financial capacity to develop the newly licensed and acquired platforms.

Negative Equity And High Debt

High debt combined with negative shareholders' equity signals limited balance-sheet resilience and accumulated financial deterioration. This structure can constrain financing choices, increase refinancing and solvency pressure, and make it harder to absorb further losses while funding growth initiatives.

DataMeds AI News

MEDS FAQ

What was DataMeds AI’s price range in the past 12 months?
DataMeds AI lowest stock price was $0.55 and its highest was $35.51 in the past 12 months.
What is DataMeds AI’s market cap?
DataMeds AI’s market cap is $3.91M.
When is DataMeds AI’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were DataMeds AI’s earnings last quarter?
DataMeds AI released its earnings results on Nov 13, 2026. The company reported $2.673 earnings per share for the quarter.
Is DataMeds AI overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does DataMeds AI pay dividends?
DataMeds AI does not currently pay dividends.
What is DataMeds AI’s EPS estimate?
DataMeds AI’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DataMeds AI have?
DataMeds AI has 4,515,862 shares outstanding.
What happened to DataMeds AI’s price movement after its last earnings report?
DataMeds AI reported an EPS of $2.673 in its last earnings report. Following the earnings report the stock price went down -14.598%.
Which hedge fund is a major shareholder of DataMeds AI?
Currently, no hedge funds are holding shares in MEDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology